Townsquare Capital LLC Raises Stake in IQVIA Holdings Inc. (NYSE:IQV)

Townsquare Capital LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,214 shares of the medical research company’s stock after purchasing an additional 666 shares during the quarter. Townsquare Capital LLC’s holdings in IQVIA were worth $2,894,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the 3rd quarter valued at approximately $27,000. Park Place Capital Corp acquired a new stake in IQVIA in the third quarter valued at $28,000. Versant Capital Management Inc increased its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth $27,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA in the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on IQV. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barclays dropped their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Morgan Stanley decreased their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, Robert W. Baird cut their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Down 0.3 %

IQV opened at $200.84 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $36.45 billion, a PE ratio of 26.36, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The firm has a 50 day moving average price of $218.67 and a 200 day moving average price of $226.17. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.